Статьи: Важнейшие открытия последних 50 лет в гинекологической патологии

1. zur Hausen H. Papillomaviruses in the causation of human
cancers – a brief historical account. Virology 2009; 384; 260–
265.
2. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillo- €
mavirus DNA from a cervical carcinoma and its prevalence in
cancer biopsy samples from different geographic regions. Proc.
Natl Acad. Sci. USA 1983; 80; 3812–3815.
3. Taylor CR, Burns J. The demonstration of plasma cells and
other immunoglobulin-containing cells in formalin-fixed, paraffin-embedded tissues using peroxidase-labelled antibody. J. Clin.
Pathol. 1974; 27; 14–20.
4. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1
assists in distinguishing ovarian from uterine serous carcinoma
and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44; 109–115.
5. Darragh TM, Colgan TJ, Thomas Cox J et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations
from the College of American Pathologists and the American
Society for Colposcopy and Cervical Pathology. Int. J. Gynecol.
Pathol. 2013; 32; 76–115.
6. Kobel M, Piskorz AM, Lee S € et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J. Pathol. Clin. Res. 2016; 2; 247–258.
7. Castrillon DH, Sun D, Weremowicz S et al. Discrimination of
complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2.
Am. J. Surg. Pathol. 2001; 25; 1225–1230.
8. Foster LN, Montgomery R. Endometrial carcinoma: a review of
previous biopsies. Am. J. Clin. Pathol. 1965; 43; 26–38.
9. Gusberg SB, Kaplan AL. Precursors of corpus cancer. IV. Adenomatous hyperplasia as stage 0 carcinoma of the endometrium. Am. J. Obstet. Gynecol. 1963; 87; 662–678.
10. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of ‘untreated’ hyperplasia
in 170 patients. Cancer 1985; 56; 403–412.
11. Mutter G. Histopathology of genetically defined endometrial
precancers. Int. J. Gynecol. Pathol. 2000; 19; 301–309.
12. Lauchlan SC. Tubal (serous) carcinoma of the endometrium.
Arch. Pathol. Lab. Med. 1981; 105; 615–618.
13. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of
endometrial adenocarcinoma. Am. J. Surg. Pathol. 1982; 6;
93–108.
14. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous
carcinoma of the ovary. A distinctive low-grade carcinoma
related to serous borderline tumors. Am. J. Surg. Pathol. 1996;
20; 1319–1330.
15. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in
prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001; 195;
451–456.
16. Lee Y, Medeiros F, Kindelberger D et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer
screening and the pathogenesis of ovarian cancer. Adv. Anat.
Pathol. 2006; 13; 1–7.
17. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas
(so-called mesonephromas). Cancer 1970; 25; 745–757.
18. Silverberg S, Makowski EL. Endometrial carcinoma in young
women taking oral contraceptive agents. Obstet. Gynecol.
1975; 46; 503–506.
19. Silverberg SG, Mullen D, Faraci JA et al. Endometrial carcinoma: clinical-pathologic comparison of cases in postmenopausal women receiving and not receiving exogenous
estrogens. Cancer 1980; 45; 3018–3026.